These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35857415)

  • 41. Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study.
    D'Hondt V; Goffin F; Roca L; Dresse D; Leroy C; Kerger J; Cordier L; de Forges H; Veys I; Liberale G
    Int J Gynecol Cancer; 2016 Jun; 26(5):912-7. PubMed ID: 27051055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
    Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
    J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on.
    Koole SN; van Driel WJ; Sonke GS
    Cancer; 2019 Dec; 125 Suppl 24():4587-4593. PubMed ID: 31967678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
    Charo LM; Jou J; Binder P; Hohmann SF; Saenz C; McHale M; Eskander RN; Plaxe S
    Gynecol Oncol; 2020 Dec; 159(3):681-686. PubMed ID: 32977989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
    Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
    Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
    Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer.
    Vergote I; Harter P; Chiva L
    Cancer; 2019 Dec; 125 Suppl 24():4594-4597. PubMed ID: 31967685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
    Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
    J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
    Lim PQ; Han IH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.
    Huo YR; Richards A; Liauw W; Morris DL
    Eur J Surg Oncol; 2015 Dec; 41(12):1578-89. PubMed ID: 26453145
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.
    Behbakht K; Cohn DE; Straughn JM
    Gynecol Oncol; 2018 Oct; 151(1):4-5. PubMed ID: 30068488
    [No Abstract]   [Full Text] [Related]  

  • 52. Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
    Zivanovic O; Chi DS; Zhou Q; Iasonos A; Konner JA; Makker V; Grisham RN; Brown AK; Nerenstone S; Diaz JP; Schroeder ED; Langstraat CL; Paroder V; Lakhman Y; Soldan K; Su K; Gardner GJ; Andikyan V; Guo J; Jewell EL; Long Roche K; Troso-Sandoval T; Lichtman SM; Moukarzel LA; Dessources K; Abu-Rustum NR; Aghajanian C; Tew WP; Beumer J; Sonoda Y; O'Cearbhaill RE
    J Clin Oncol; 2021 Aug; 39(23):2594-2604. PubMed ID: 34019431
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
    Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
    Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer.
    Brennan DJ; Driel WJV; Zivanovic O
    Int J Gynecol Cancer; 2023 May; 33(5):851-852. PubMed ID: 36898700
    [No Abstract]   [Full Text] [Related]  

  • 55. Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Le Saux O; Decullier E; Freyer G; Glehen O; Bakrin N
    Int J Hyperthermia; 2018; 35(1):652-657. PubMed ID: 30295114
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study.
    Petrillo M; Zucchetti M; Cianci S; Morosi L; Ronsini C; Colombo A; D'Incalci M; Scambia G; Fagotti A
    J Gynecol Oncol; 2019 Jul; 30(4):e59. PubMed ID: 31074245
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is There a Role for Intraperitoneal Chemotherapy, Including HIPEC, in the Management of Ovarian Cancer?
    Vergote I; Harter P; Chiva L
    J Clin Oncol; 2019 Sep; 37(27):2420-2423. PubMed ID: 31403870
    [No Abstract]   [Full Text] [Related]  

  • 58. A phase 2 trial of short-course Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) at interval cytoreductive surgery (iCRS) for advanced ovarian cancer.
    Batista TP; Carneiro VCG; Tancredi R; Badiglian Filho L; Rangel RLC; Lopes A; Sarmento BJQ; Leão CS
    Rev Col Bras Cir; 2022; 49():e20223135. PubMed ID: 35239855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?
    Ghirardi V; De Felice F; D'Indinosante M; Bernardini F; Giudice MT; Fagotti A; Scambia G
    Cancer Treat Res Commun; 2022; 31():100518. PubMed ID: 35065323
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020).
    Farrell R; Burling M; Lee YC; Pather S; Robledo K; Mercieca-Bebber R; Stockler M;
    J Gynecol Oncol; 2022 Jan; 33(1):e1. PubMed ID: 34783204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.